Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Change in Receivables (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Change in Receivables data on record, last reported at -$1.9 million in Q3 2025.

  • For Q3 2025, Change in Receivables fell 5041.03% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached $654000.0, up 154.32%, while the annual FY2024 figure was $665000.0, 53.69% down from the prior year.
  • Change in Receivables reached -$1.9 million in Q3 2025 per SNTI's latest filing, down from $1.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $2.6 million in Q3 2023 and bottomed at -$1.9 million in Q3 2025.
  • Average Change in Receivables over 5 years is $139562.5, with a median of $9000.0 recorded in 2024.
  • The widest YoY moves for Change in Receivables: up 3510.71% in 2025, down 5041.03% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $50000.0 in 2021, then skyrocketed by 162.0% to $131000.0 in 2022, then plummeted by 990.08% to -$1.2 million in 2023, then surged by 160.29% to $703000.0 in 2024, then crashed by 374.11% to -$1.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$1.9 million in Q3 2025, $1.9 million in Q2 2025, and -$32000.0 in Q1 2025.